Global CAR T therapy trial shows high rates of durable remission for NHL
In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) ...
Dec 10, 2017
0
0